Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ADIS INT LTD
Autores
TORRES, Tiago
CHIRICOZZI, Andrea
PUIG, Luis
LE, Ana Maria
MARZANO, Angelo Valerio
DAPAVO, Paolo
DAUDEN, Esteban
CARRASCOSA, Jose-Manuel
LAZARIDOU, Elizabeth
DUARTE, Gleison
Citação
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, v.25, n.2, p.333-342, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundTuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials and real-world studies suggests that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis reactivation.ObjectiveTo evaluate psoriasis patients with treated or untreated newly diagnosed LTBI who received IL-17 and IL-23 inhibitors and the tolerability/safety of tuberculosis chemoprophylaxis.MethodsThis is a retrospective, observational, multinational study from a series of 14 dermatology centres based in Portugal, Spain, Italy, Greece and Brazil, which included adult patients with moderate-to-severe chronic plaque psoriasis and newly diagnosed LTBI who were treated with IL-23 or IL-17 inhibitors between January 2015 and March 2022. LTBI was diagnosed in the case of tuberculin skin test and/or interferon gamma release assay positivity, according to local guideline, prior to initiating IL-23 or IL-17 inhibitor. Patients with prior diagnosis of LTBI (treated or untreated) or treated active infection were excluded.ResultsA total of 405 patients were included; complete/incomplete/no chemoprophylaxis was administered in 62.2, 10.1 and 27.7% of patients, respectively. The main reason for not receiving or interrupting chemoprophylaxis was perceived heightened risk of liver toxicity and hepatotoxicity, respectively. The mean duration of biological treatment was 32.87 +/- 20.95 months, and only one case of active tuberculosis infection (ATBI) was observed, after 14 months of treatment with ixekizumab. The proportion of ATBI associated with ixekizumab was 1.64% [95% confidence interval (CI): 0-5.43%] and 0% for all other agents and 0.46% (95% CI 0-1.06%) and 0% for IL-17 and IL-23 inhibitors, respectively (not statistically significant).ConclusionsThe risk of tuberculosis reactivation in patients with psoriasis and LTBI does not seem to increase with IL-17 or IL-23 inhibitors. IL-17 or IL-23 inhibitors should be preferred over TNF antagonists when concerns regarding tuberculosis reactivation exists. In patients with LTBI considered at high risk for developing complications related to chemoprophylaxis, this preventive strategy may be waived before initiating treatment with IL-17 inhibitors and especially IL-23 inhibitors.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59194
Referências
  1. Ai JW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.10
  2. [Anonymous], 2015, Guidelines on the management of latent tuberculosis infection
  3. Ardain A, 2019, NATURE, V570, P528, DOI 10.1038/s41586-019-1276-2
  4. Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006
  5. Blauvelt A, 2018, BRIT J DERMATOL, V179, P615, DOI 10.1111/bjd.16724
  6. Cagatay AA, 2004, SCAND J INFECT DIS, V36, P799, DOI 10.1080/00365540410025339
  7. Cantini F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8909834
  8. Cantini F, 2015, AUTOIMMUN REV, V14, P503, DOI 10.1016/j.autrev.2015.01.011
  9. Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851
  10. Chackerian AA, 2006, INFECT IMMUN, V74, P6092, DOI 10.1128/IAI.00621-06
  11. Chung-Delgado K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027610
  12. Denholm JT, 2014, DRUG HEALTHC PATIENT, V6, P145, DOI 10.2147/DHPS.S68837
  13. Deodhar A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1882-2
  14. Dixon WG, 2010, ANN RHEUM DIS, V69, P522, DOI 10.1136/ard.2009.118935
  15. Errichetti E, 2014, EUR J DERMATOL, V24, P508, DOI 10.1684/ejd.2014.2386
  16. Fiorella C, 2022, CLIN CASE REP, V10, DOI 10.1002/ccr3.5302
  17. Gerdes S, 2020, J DERMATOL TREAT, V31, P470, DOI 10.1080/09546634.2020.1746734
  18. Harrington T., 2010, Morbidity and Mortality Weekly Report, V59, P224
  19. Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013
  20. Huang YW, 2020, EXPERT OPIN DRUG SAF, V19, P395, DOI 10.1080/14740338.2020.1736034
  21. Ibba L, 2023, J DERMATOL TREAT, V34, DOI 10.1080/09546634.2023.2241585
  22. Kabbara WK, 2016, CASE REP INFECT DIS, V2016, DOI 10.1155/2016/3617408
  23. Kammüller M, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.34
  24. Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567
  25. Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788
  26. Kleinschek MA, 2006, J IMMUNOL, V176, P1098, DOI 10.4049/jimmunol.176.2.1098
  27. Lee SH, 2012, EPIDEMIOL INFECT, V140, P1028, DOI 10.1017/S0950268811001476
  28. Leonardi C, 2020, DERMATOLOGY THER, V10, P431, DOI 10.1007/s13555-020-00367-x
  29. Li Andrew A, 2018, Diseases, V6, DOI 10.3390/diseases6020040
  30. LoBue PA, 2017, LANCET INFECT DIS, V17, pE327, DOI 10.1016/S1473-3099(17)30248-7
  31. Lyadova IV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/854507
  32. Lynch Maeve, 2017, JAAD Case Rep, V3, P230, DOI 10.1016/j.jdcr.2017.02.001
  33. Machado A, 2020, EUR J DERMATOL, V30, P740, DOI 10.1684/ejd.2020.3909
  34. MacNeil A, 2019, MMWR-MORBID MORTAL W, V68, P263, DOI 10.15585/mmwr.mm6811a3
  35. Manzanares Nerea, 2024, J Eur Acad Dermatol Venereol, V38, pe26, DOI 10.1111/jdv.19406
  36. Megna M, 2022, J DERMATOL TREAT, V33, P2629, DOI 10.1080/09546634.2022.2062280
  37. Metushi I, 2016, BRIT J CLIN PHARMACO, V81, P1030, DOI 10.1111/bcp.12885
  38. Miller EA, 2009, J CLIN INVEST, V119, P1079, DOI 10.1172/JCI39143
  39. Miyazawa S, 2015, INTERNAL MED, V54, P591, DOI 10.2169/internalmedicine.54.3669
  40. Mourik BC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00294
  41. Mrowietz U, 2020, J AM ACAD DERMATOL, V83, P1436, DOI 10.1016/j.jaad.2020.06.012
  42. Niemi M, 2003, CLIN PHARMACOKINET, V42, P819, DOI 10.2165/00003088-200342090-00003
  43. Nogueira M, 2021, J EUR ACAD DERMATOL, V35, P824, DOI 10.1111/jdv.16866
  44. Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475
  45. Ribero S, 2019, CASE REP DERMATOL, V11, P23, DOI 10.1159/000501989
  46. Robert M, 2021, CELL MOL IMMUNOL, V18, P1644, DOI 10.1038/s41423-021-00694-9
  47. Shu D, 2020, DERMATOL THER, V33, DOI 10.1111/dth.14512
  48. Singh S, 2018, J PATHOL, V244, P311, DOI 10.1002/path.5013
  49. Smith CH, 2020, BRIT J DERMATOL, V183, P628, DOI 10.1111/bjd.19039
  50. Snast I, 2019, AM J CLIN DERMATOL, V20, P483, DOI 10.1007/s40257-019-00432-y
  51. Souto A, 2014, RHEUMATOLOGY, V53, P1872, DOI 10.1093/rheumatology/keu172
  52. Sterling T.R., 2020, MMWR Recomm. Rep, V69, DOI 10.15585/MMWR.RR6901A1
  53. Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
  54. Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x
  55. Tsai TF, 2013, BRIT J DERMATOL, V168, P444, DOI 10.1111/j.1365-2133.2012.11162.x
  56. Tsai TF, 2012, BRIT J DERMATOL, V167, P1145, DOI 10.1111/j.1365-2133.2012.11142.x
  57. Zhang Z, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012567

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC